Barclays PLC Buys 19,030 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT)

Barclays PLC lifted its stake in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 17.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 125,204 shares of the company’s stock after purchasing an additional 19,030 shares during the period. Barclays PLC owned 0.10% of Nautilus Biotechnology worth $210,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. SG Americas Securities LLC boosted its position in shares of Nautilus Biotechnology by 56.3% in the 4th quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock worth $46,000 after purchasing an additional 9,904 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Nautilus Biotechnology in the 4th quarter worth $28,000. JPMorgan Chase & Co. lifted its holdings in Nautilus Biotechnology by 309.9% during the fourth quarter. JPMorgan Chase & Co. now owns 145,937 shares of the company’s stock worth $245,000 after acquiring an additional 110,334 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Nautilus Biotechnology by 61.7% during the fourth quarter. Renaissance Technologies LLC now owns 250,221 shares of the company’s stock worth $420,000 after acquiring an additional 95,521 shares in the last quarter. Finally, Palumbo Wealth Management LLC lifted its holdings in Nautilus Biotechnology by 45.4% during the fourth quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company’s stock worth $48,000 after acquiring an additional 8,888 shares in the last quarter. 50.71% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Guggenheim set a $2.50 target price on Nautilus Biotechnology in a report on Friday, February 28th.

Insider Activity

In other news, CEO Sujal M. Patel purchased 53,300 shares of the business’s stock in a transaction dated Wednesday, March 19th. The shares were bought at an average cost of $0.99 per share, for a total transaction of $52,767.00. Following the completion of the acquisition, the chief executive officer now directly owns 10,117,788 shares in the company, valued at approximately $10,016,610.12. This trade represents a 0.53% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have bought a total of 66,800 shares of company stock worth $62,622 over the last three months. Corporate insiders own 40.50% of the company’s stock.

Nautilus Biotechnology Trading Up 3.3%

NAUT stock opened at $0.72 on Tuesday. The business’s 50-day moving average price is $0.84 and its two-hundred day moving average price is $1.57. The firm has a market cap of $91.21 million, a PE ratio of -1.29 and a beta of 1.41. Nautilus Biotechnology, Inc. has a 1-year low of $0.66 and a 1-year high of $3.09.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its earnings results on Tuesday, April 29th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.01. On average, analysts forecast that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current year.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.